|
1
|
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
|
Clin Infect Dis
|
2009
|
22.98
|
|
2
|
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.
|
J Infect Dis
|
2008
|
5.05
|
|
3
|
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.
|
Ann Intern Med
|
2004
|
4.75
|
|
4
|
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases.
|
Antimicrob Agents Chemother
|
2003
|
3.92
|
|
5
|
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.
|
J Antimicrob Chemother
|
2009
|
3.82
|
|
6
|
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
|
Clin Infect Dis
|
2004
|
3.75
|
|
7
|
A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway.
|
J Biol Chem
|
2005
|
2.18
|
|
8
|
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
|
Antimicrob Agents Chemother
|
2009
|
2.12
|
|
9
|
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
|
Antimicrob Agents Chemother
|
2008
|
1.89
|
|
10
|
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes.
|
Antimicrob Agents Chemother
|
2005
|
1.88
|
|
11
|
Intrinsic and acquired resistance mechanisms in enterococcus.
|
Virulence
|
2012
|
1.59
|
|
12
|
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
|
Antimicrob Agents Chemother
|
2004
|
1.58
|
|
13
|
Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates.
|
J Clin Microbiol
|
2010
|
1.55
|
|
14
|
Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients.
|
J Microbiol Methods
|
2003
|
1.54
|
|
15
|
Cotransfer of antibiotic resistance genes and a hylEfm-containing virulence plasmid in Enterococcus faecium.
|
Antimicrob Agents Chemother
|
2009
|
1.51
|
|
16
|
Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
|
J Biol Chem
|
2007
|
1.46
|
|
17
|
Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.
|
Antimicrob Agents Chemother
|
2003
|
1.42
|
|
18
|
Specificity of L,D-transpeptidases from gram-positive bacteria producing different peptidoglycan chemotypes.
|
J Biol Chem
|
2007
|
1.34
|
|
19
|
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.
|
Antimicrob Agents Chemother
|
2011
|
1.26
|
|
20
|
The hylEfm gene in pHylEfm of Enterococcus faecium is not required in pathogenesis of murine peritonitis.
|
BMC Microbiol
|
2011
|
1.18
|
|
21
|
Inactivation kinetics of a new target of beta-lactam antibiotics.
|
J Biol Chem
|
2011
|
1.11
|
|
22
|
Analysis of PBP5 of early U.S. isolates of Enterococcus faecium: sequence variation alone does not explain increasing ampicillin resistance over time.
|
Antimicrob Agents Chemother
|
2011
|
1.06
|
|
23
|
Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?
|
Clin Infect Dis
|
2003
|
1.01
|
|
24
|
Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies.
|
PLoS One
|
2013
|
1.00
|
|
25
|
Activation of the L,D-transpeptidation peptidoglycan cross-linking pathway by a metallo-D,D-carboxypeptidase in Enterococcus faecium.
|
Mol Microbiol
|
2009
|
0.99
|
|
26
|
A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C beta-lactamase: an emerging concern in pediatrics?
|
Microb Drug Resist
|
2002
|
0.95
|
|
27
|
Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium.
|
J Biol Chem
|
2006
|
0.92
|
|
28
|
Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model.
|
PLoS One
|
2013
|
0.89
|
|
29
|
Antibiotic-induced enterococcal expansion in the mouse intestine occurs throughout the small bowel and correlates poorly with suppression of competing flora.
|
Antimicrob Agents Chemother
|
2006
|
0.88
|
|
30
|
Kinetic features of L,D-transpeptidase inactivation critical for β-lactam antibacterial activity.
|
PLoS One
|
2013
|
0.88
|
|
31
|
Peptidoglycan cross-linking in glycopeptide-resistant Actinomycetales.
|
Antimicrob Agents Chemother
|
2014
|
0.85
|
|
32
|
Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase.
|
Antimicrob Agents Chemother
|
2005
|
0.85
|
|
33
|
Kinetic analysis of Enterococcus faecium L,D-transpeptidase inactivation by carbapenems.
|
Antimicrob Agents Chemother
|
2012
|
0.84
|
|
34
|
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities.
|
Clin Infect Dis
|
2002
|
0.83
|
|
35
|
Effect of parenteral fluoroquinolone administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.
|
Antimicrob Agents Chemother
|
2004
|
0.82
|
|
36
|
Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.
|
Antimicrob Agents Chemother
|
2012
|
0.81
|
|
37
|
Bacteria by the book.
|
Science
|
2008
|
0.80
|
|
38
|
Evidence-based evaluation of physician work hour regulations.
|
JAMA
|
2009
|
0.80
|
|
39
|
An interventional program to improve antibiotic use.
|
Ann Pharmacother
|
2003
|
0.79
|
|
40
|
A novel genetic region flanks the plasmid-carried blaNDM-1 isolated from a patient in Rhode Island in 2012.
|
Antimicrob Agents Chemother
|
2013
|
0.78
|
|
41
|
Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae?
|
Sex Transm Infect
|
2015
|
0.78
|
|
42
|
Collateral damage.
|
Ann Intern Med
|
2003
|
0.78
|
|
43
|
Gastrointestinal bacteria will have its way.
|
J Infect Dis
|
2012
|
0.77
|
|
44
|
In memoriam: John P. Quinn, MD.
|
Clin Infect Dis
|
2013
|
0.75
|
|
45
|
High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium.
|
Emerg Infect Dis
|
2017
|
0.75
|